Xenon Pharmaceuticals Inc

Explore Xenon Pharmaceuticals’ biotech journey, stock volatility, and its focus on ion‑channel therapies and gene‑therapy Glybera, plus key financial insights.

Explore Xenon Pharmaceuticals’ new equity grants, market rebound, and promising epilepsy data that could drive its biotech future.

Xenon Pharmaceuticals Inc. is a clinical-stage biotech company pioneering gene therapy, particularly with its product Glybera, which aims to treat a rare lipid disorder with a lasting solution.

Xenon Pharmaceuticals Inc. is making progress in 2025 with promising developments in its clinical-stage endeavors, including advancements in Phase 3 programs for epilepsy and psychiatry.